« Zurück
Startseite /
Human CXCL13/BCA-1 Protein (CXC-HM213)

Human CXCL13/BCA-1 Protein (CXC-HM213)

ArtNr	CXC-HM213-100UG
Hersteller	KactusBio
Menge	100 ug
Quantity options	100 ug 500 ug
Kategorie	Oncology By Cell Type Hematology Peptides & Proteins Recombinant Proteins Lymphom
Typ	Proteins Recombinant
Format	Lyophilized
Specific against	Human (Homo sapiens)
Host	HEK293
Konjugat/Tag	N-hFc
Purity	> 95% as determined by Bis-Tris PAGE;> 95% as determined by HPLC
Formula	Supplied as 0.22μm filtered solution in 50mM Tris,500mM NaCl (pH 7.4).
Sequence	Val23-Per109
ECLASS 10.1	32160409
ECLASS 11.0	32160409
UNSPSC	12352202
Alias	ANGIE,ANGIE2,BCA-1,BCA1,BLC,BLR1L,SCYB13
Versandbedingung	Raumtemperatur
Lieferbar
Manufacturer - Type	Recombinant Protein
Manufacturer - Targets	CXCL13/BCA-1
Shipping Temperature	Shipped at ambient temperature.
Storage Conditions	-20 to -80°C for 12 months as supplied from date of receipt.；-80°C for 3 months after reconstitution.；Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Molecular Weight	The protein has a predicted MW of 37.6 kDa. Due to glycosylation, the protein migrates to 42-50 kDa based on Bis-Tris PAGE result.
Description	Recombinant Human CXCL13/BCA-1 Protein is expressed from HEK293 with hFc tag at the N-Terminus.It contains Val23-Per109.
Background	Recent studies have implicated chemokines in microglial activation and pathogenesis of neuropathic pain. C-X-C motif chemokine 13 (CXCL13) is a B lymphocyte chemoattractant that activates CXCR5. Using the spinal nerve ligation (SNL) model of neuropathic pain, CXCL13 was persistently upregulated in spinal cord neurons after SNL, resulting in spinal astrocyte activation via CXCR5 in mice.
Endotoxin	Less than 1 EU per μg by the LAL method.
Formulation	Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Reconstitution	Dissolve the lyophilized protein in distilled water. It is recommended to resuspend at 0.5 mg/mL if the lyophilized powder is 100 μg or less, at 1mg/ml for 500μg or 1mg lyophilized powder. Do not mix by vortex or vigorous shaking.
Biotinylated	no

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.

Arbeitsanleitung (Data Sheet) anfordern

CXC-HM213-100UG-datasheet.pdf

CXC-HM213-100UG-safety-datasheet.pdf